Beranda › Kanker Paru Non-Sel Kecil › New York › Syracuse
Uji klinis Kanker Paru Non-Sel Kecil di Syracuse, NY
15 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Syracuse (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Menerima pesertaFase 3
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse · 4 mi jauhnya
- Hematology Oncology Associates of CNY at Camillus, Camillus · 8 mi jauhnya
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- State University of New York Upstate Medical University, Syracuse
- SUNY Upstate Medical Center-Community Campus, Syracuse
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse · 4 mi jauhnya
- dan 1 lainnya
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Menerima pesertaFase 2
- State University of New York Upstate Medical University, Syracuse
- Upstate Cancer Center at Hill Radiation Oncology, Syracuse
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Menerima pesertaFase 3
- SUNY Upstate Cancer Center ( Site 0140), Syracuse
- Hematology-Oncology Associates of CNY ( Site 0164), East Syracuse · 4 mi jauhnya
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #76, Syracuse
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Research Site, East Syracuse · 4 mi jauhnya
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Hematology-Oncology Associates of CNY, East Syracuse · 4 mi jauhnya
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Menerima pesertaFase 3
- SUNY Upstate Medical University, Syracuse
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- Research Site, East Syracuse · 4 mi jauhnya
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Menerima pesertaFase 3
- Clinical Study Site, Syracuse
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- SUNY Upstate Medical University, Syracuse
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Menerima pesertaFase 3
- Research Site, East Syracuse · 4 mi jauhnya
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Menerima pesertaFase 3
- State University of New York Upstate Medical University, Syracuse
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Menerima pesertaFase 3
- SUNY - Upsate Medical Centre, Syracuse
GEMINI-NSCLC: NSCLC Biomarker Study
Menerima pesertaStudi observasional
- Hematology Oncology Associates of Central New York, East Syracuse · 4 mi jauhnya
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Studi lain di Syracuse
- Kanker (semua jenis)9 studi
- Kanker Prostat9 studi
- Kanker Kandung Kemih Non-Invasif Otot8 studi
- Kanker Ovarium7 studi
- Kanker Endometrium7 studi
- Obesitas6 studi
- Kanker Paru6 studi
- Kanker Kolorektal5 studi
- Degenerasi Makula5 studi
- Leukemia Mieloid Akut5 studi
- Diabetes Tipe 25 studi
- Lupus5 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.